Recursion Pharmaceuticals (RXRX) closed at $4.05 in the latest trading session, marking a +2.02% move from the prior day. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq ...

Recursion Pharmaceuticals RXRX continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its ...

Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, ...